You’ve tried multiple antidepressants. You’ve given each one time to work, endured the side effects, adjusted the dosages. Yet here you are, still struggling with depression that refuses to budge. If this sounds familiar, you’re not alone, and more importantly, you’re not out of options. At Nura Therapy, we’ve seen how Spravato for treatment-resistant depression can create real turning points in people’s lives when traditional treatments haven’t delivered the relief they desperately need.
Treatment-resistant depression affects roughly 30% of people with major depressive disorder. That’s millions of Americans who’ve done everything “right” but still can’t find relief. The emergence of Spravato (esketamine nasal spray) represents a fundamentally different approach, one backed by clinical research and, more importantly, by real stories of people reclaiming their lives.
What Makes Depression “Treatment-Resistant”?
Depression becomes classified as treatment-resistant when you haven’t responded adequately to at least two different antidepressant medications from different classes, taken at appropriate doses for sufficient duration. It’s not a reflection of personal failure. Your brain chemistry simply isn’t responding to the traditional mechanisms that help most people.
The statistics tell a sobering story. Research published in the American Journal of Psychiatry shows that with each failed medication trial, your likelihood of responding to the next traditional antidepressant drops significantly. After two unsuccessful trials, you’re in treatment-resistant territory. After four or more failed attempts, the odds of a conventional medication working fall below 10%.
This isn’t just about feeling sad. Treatment-resistant depression often involves profound emotional numbness, overwhelming fatigue, cognitive fog that makes simple tasks feel impossible, and sometimes dangerous thoughts of self-harm. The longer it persists, the more it affects your relationships, career, and fundamental sense of self.
How Spravato Works Differently
Here’s where things get interesting. While traditional antidepressants work primarily on serotonin, norepinephrine, or dopamine systems and can take weeks or months to show benefits, Spravato for treatment-resistant depression takes a completely different route.
Esketamine, the active ingredient in Spravato, targets the glutamate system in your brain, specifically NMDA receptors. Think of it like this: if traditional antidepressants slowly adjust the volume on your brain’s existing channels, Spravato helps create new connections between neurons. It promotes something called neuroplasticity, essentially helping your brain build new pathways around the patterns that have kept you stuck in depression.
The FDA approved Spravato treatment specifically for treatment-resistant depression in 2019, making it the first truly novel antidepressant mechanism in decades. You use it as a nasal spray, administered under medical supervision, always in conjunction with an oral antidepressant.
Clinical Outcomes: What the Research Shows
Let’s talk numbers, because they matter. The pivotal clinical trials that led to FDA approval showed consistent results across multiple studies.
In the TRANSFORM-1 trial, patients receiving Spravato alongside an oral antidepressant showed significantly greater improvement compared to those receiving a placebo. The difference wasn’t subtle, with meaningful reductions in depression severity scores at 28 days and many patients continuing to improve over longer periods.
The SUSTAIN-1 study tracked patients for up to a year and found that those who responded well to initial Spravato treatment were far less likely to relapse compared to those switched to placebo. Specifically, 70% of patients maintained their improvement while continuing Spravato treatment, compared to only 30% of those who discontinued it.
More recent research published in JAMA Psychiatry reinforces these findings. Patients with treatment-resistant depression who received esketamine nasal spray plus an oral antidepressant were approximately three times more likely to achieve remission than those receiving placebo plus an oral antidepressant.
Here’s something that often gets overlooked in discussions about depression treatment: speed matters. When you’ve been suffering for months or years, waiting another six to eight weeks for a medication to potentially work feels interminable. Many patients report noticing improvements within hours or days of their first Spravato treatment, not complete remission necessarily, but that first glimmer of hope, that lifting of the heaviest weight.
Real Success Stories from Fort Worth
The clinical trial data matters, but so do the human stories behind it. We’ve seen transformations at our Fort Worth clinic that remind us why we do this work.
Sarah came to us after seven years of trying different antidepressants. She had been to three psychiatrists, worked with therapists, and tried combinations of medications, everything her doctors suggested. “I’d started to believe this was just how my life would be,” she told us. “I couldn’t remember what it felt like to have energy or to look forward to anything.”
After her third Spravato treatment, something shifted. Not a miracle cure, that’s not how this works, but a noticeable lightening. By the end of her induction phase, she described it as “the fog finally lifting enough that I could see a path forward.” Two years later, with maintenance treatments every few weeks, she’s working full-time again and reconnected with hobbies she’d abandoned.
Marcus, a veteran dealing with both PTSD and treatment-resistant depression, had a different experience but equally meaningful. Traditional antidepressants left him feeling either emotionally flat or too sedated to function. “Spravato gave me back the ability to feel,” he shared. “Not just the good stuff—I could feel everything, which was sometimes hard, but it meant I could finally process things that had been locked away for years, especially when combined with therapy.”
These aren’t isolated cases. Clinical data from real-world use shows response rates of 60 to 70 percent in patients with treatment-resistant depression, far higher than the 10 to 20 percent response rates typically seen when trying another traditional antidepressant after multiple failures.
What to Expect During Spravato Treatment
Understanding the practical aspects helps demystify the process. Spravato isn’t something you use at home. You’ll come to our Fort Worth clinic for each treatment session, which typically takes about two hours total.
Here’s how a typical session unfolds: First, we check your blood pressure and review how you’re feeling. You’ll self-administer the nasal spray under our supervision. It’s a simple process, though the taste can be slightly bitter. Then comes the monitoring period. You’ll rest in a comfortable treatment room while the medication takes effect.
Some people feel nothing dramatic. Others experience mild dissociation, a dreamlike state or feeling of detachment that typically fades within 30 to 60 minutes. This isn’t dangerous; it’s actually related to how the medication works on your brain. We monitor you the entire time, checking vital signs and making sure you’re comfortable.
The induction phase typically involves twice-weekly treatments for four weeks. If you respond well, we transition to maintenance treatments. How often? That varies by individual, with some people doing well with weekly sessions and others needing treatment only every two to three weeks.
You can’t drive yourself home after treatment, so plan accordingly. The effects that make driving unsafe wear off within a couple hours, but it’s a safety requirement. Most people return to normal activities the same day.
Combining Spravato with Other Treatments
One crucial thing to understand: Spravato for treatment-resistant depression isn’t a standalone treatment. The FDA approval specifically requires using it alongside an oral antidepressant. Think of it as a combination therapy where each component supports the other.
We often recommend ketamine-assisted psychotherapy to enhance and extend Spravato’s benefits. The neuroplasticity that esketamine promotes creates a window of opportunity where therapy can be particularly effective. You’re not just getting temporary symptom relief—you’re potentially rewiring how your brain processes emotions and experiences.
Some patients at our Fort Worth clinic continue their regular therapy sessions, adding Spravato to support that work. Others find that combining esketamine treatment with trauma-focused therapy helps them finally process experiences that traditional approaches couldn’t touch.
The goal isn’t just to feel less depressed. It’s to build sustainable changes that persist between treatments and, eventually, reduce how often you need them.
Is Spravato Right for You?
Not everyone with treatment-resistant depression is a candidate for Spravato treatment. The FDA approval comes with specific criteria:
- Diagnosed major depressive disorder
- Inadequate response to at least two different oral antidepressants in the current episode
- Willing to use the medication only under medical supervision
- No history of certain conditions that could make esketamine unsafe (like uncontrolled high blood pressure or a history of bleeding in the brain)
Age matters too. Spravato is approved for adults with treatment-resistant depression. It also has FDA approval for adults with major depressive disorder experiencing acute suicidal ideation or behavior, a separate indication that highlights its potentially life-saving rapid action.
We evaluate each person individually at Nura Therapy. Your medical history, current medications, specific symptoms, and treatment goals all factor into whether Spravato makes sense for your situation. Sometimes, trying standard ketamine therapy first makes more sense, depending on insurance coverage and individual circumstances.
Insurance Coverage and Access
Here’s something that matters to nearly everyone: cost and coverage. Spravato carries FDA approval specifically for treatment-resistant depression, meaning many insurance plans cover it, often more readily than IV ketamine treatments.
That said, coverage isn’t universal. Most insurers require documentation of previous treatment failures and may have specific protocols for approval. Some require that you’ve tried a certain number of medications from different classes. Prior authorization is standard, and the process can take a few weeks.
The out-of-pocket cost varies dramatically depending on your insurance. With coverage, you might pay a copay similar to specialty medications. Without insurance, the cost is significant, though manufacturer assistance programs sometimes help bridge the gap for those who qualify.
We work with patients at our Fort Worth clinic to navigate the insurance process. It’s frustrating, honestly. When someone is suffering from treatment-resistant depression, adding paperwork hurdles feels cruel. But FDA approval and the designation as a breakthrough therapy have made access far better than it was even a few years ago.
Safety Considerations and Side Effects
Let’s be straight about side effects. Spravato isn’t without them, though most are manageable and temporary.
Common side effects during and shortly after treatment include dizziness, nausea, dissociation, increased blood pressure, and sedation. These typically peak within 40 minutes of administration and resolve within 90 minutes. That’s why you’re monitored the entire time and can’t drive yourself home.
Some people experience a bad taste in their mouth or nasal discomfort since it is a nasal spray.
Occasionally, people feel anxious or strange during the dissociative period. We’re there to support you through any discomfort, and knowing these effects are temporary and expected helps most people manage them fine.
Long-term safety data from clinical trials extending beyond a year shows no new concerning safety signals emerging with continued use. The most common reason people discontinue isn’t side effects, it’s lack of efficacy or difficulty maintaining the required treatment schedule.
Serious adverse events are rare but include increased blood pressure that could be dangerous for people with uncontrolled hypertension or cardiovascular disease. This is why screening and monitoring are so important.
The Science Behind Long-Term Outcomes
Research on long-term outcomes with Spravato for treatment-resistant depression continues to grow. A study published in the Journal of Clinical Psychiatry followed patients for up to a year and found sustained efficacy in those who continued treatment. Only a small percentage discontinued due to worsening depression, suggesting that the benefits are maintainable over time with appropriate dosing.
Compare this to data from the famous STAR*D study, which tracked outcomes in treatment-resistant depression using conventional approaches. That research showed relapse rates of 65-71% during the first year after initially responding to a third or fourth medication trial. Spravato’s maintenance data looks substantially better.
Why does this matter? Because treatment-resistant depression isn’t just about acute symptom relief. It’s about building a life where depression doesn’t dominate everything. Long-term efficacy means you can make plans, rebuild relationships, pursue goals—all the things that become nearly impossible when you’re constantly relapsing.
The neurobiological changes that esketamine promotes appear to have staying power, especially when reinforced with regular maintenance treatment and supportive therapy. It’s not a cure, but for many people, it’s the first treatment that actually works sustainably.
How Fort Worth Patients Access Spravato Treatment
At Nura Therapy, we’ve designed our Spravato program to be as accessible and supportive as possible. Located at 4622 Saint Amand Circle in Fort Worth, we serve patients throughout the Dallas-Fort Worth metroplex who are struggling with treatment-resistant depression.
Your first step is a comprehensive consultation. We review your treatment history, current symptoms, medical conditions, and medications. We need to verify that you meet criteria for treatment-resistant depression and that Spravato would be safe for you specifically. This isn’t a rubber stamp process, we’re thorough because your safety matters.
If you’re a good candidate, we help with the insurance pre-authorization process. Once approved, we schedule your induction phase treatments. Most people come twice weekly for the first month, though schedules can be adjusted based on your response and circumstances.
Our Fort Worth location near TCU and the Cultural District makes us accessible from throughout Tarrant County. We’ve treated patients from Arlington, Grapevine, Benbrook, and across the region—wherever people are searching for effective depression treatment that actually works when conventional approaches haven’t.
Comparing Spravato to Other Ketamine Treatments
You might be wondering: what’s the difference between Spravato and IV ketamine therapy? It’s a fair question, and the answer affects treatment decisions.
Spravato uses esketamine, which is one form of the ketamine molecule (the S-enantiomer). IV ketamine uses racemic ketamine, which contains both forms. Some research suggests racemic ketamine might be slightly more effective, while other data shows comparable results. The honest answer is both work well for many people with treatment-resistant depression.
The big practical differences:
FDA Approval: Spravato has specific FDA approval for treatment-resistant depression. Standard ketamine is used off-label for depression, which can affect insurance coverage.
Administration: Spravato is a nasal spray; ketamine therapy typically involves IV infusion. Some people strongly prefer one method over the other.
Insurance: Spravato is more likely to be covered by insurance because of FDA approval. IV ketamine is almost always out-of-pocket.
Treatment Time: Spravato sessions take about 2 hours including monitoring. IV ketamine infusions typically run 40-60 minutes with similar monitoring periods.
Dosing Control: IV administration allows for precise dose titration during the session. Nasal spray dosing is fixed, though you can take additional doses under supervision if needed.
We offer both options at Nura Therapy because different approaches work better for different people. Some patients start with Spravato due to insurance coverage, then transition to IV ketamine if they need more flexibility. Others prefer the nasal spray simplicity. There’s no single best approach, it’s about what works for you.
Beyond Symptom Relief: Quality of Life Improvements
Here’s what the clinical trials don’t fully capture: what life actually looks like when treatment-resistant depression finally responds to something.
Patients describe being able to get out of bed without it feeling like climbing a mountain. They talk about reconnecting with family members, about laughing at jokes again, about caring whether they eat something other than whatever requires the least effort.
The improvements often extend beyond mood. Cognitive fog lifts, allowing you to concentrate on tasks, remember conversations, and make decisions without feeling paralyzed by everything. Sleep patterns normalize. Physical pain that you didn’t realize was connected to depression starts to ease.
This matters because depression touches everything. Treatment-resistant depression that has persisted for years affects your career, your relationships, your physical health, your financial stability, your sense of who you are as a person. When Spravato works, the ripple effects extend far beyond a reduction in depression rating scale scores.
Research backs this up. Studies measuring quality of life improvements in people receiving esketamine treatment for treatment-resistant depression show gains across multiple domains: social functioning, physical health, psychological wellbeing, and environmental factors. These aren’t just statistical improvements, they represent people getting their lives back.
What Happens If Spravato Doesn’t Work?
We’d love to promise that Spravato for treatment-resistant depression works for everyone. It doesn’t. Response rates of 60-70% are impressive for this population, but that means 30-40% of people don’t respond adequately.
If you’re in that group, you haven’t run out of options. Sometimes switching to IV ketamine therapy produces different results. Other emerging treatments include transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT) for severe cases, or novel medications being studied in clinical trials.
At Nura Therapy, we work with your existing psychiatric team to coordinate care. If Spravato isn’t delivering the results you need, we help identify next steps rather than leaving you to figure it out alone.
It’s also worth noting that “not responding” exists on a spectrum. Some people have partial responses that aren’t enough on their own but might be meaningful when combined with other interventions. Others notice benefits in specific symptom areas, reduced suicidal thinking, better sleep, and less anxiety, even if overall depression doesn’t fully lift.
The Role of Hope in Treatment-Resistant Depression
This might sound soft, but hope itself is therapeutic. When you’ve tried multiple treatments without success, hopelessness becomes its own symptom, distinct from depression but feeding into it. The belief that nothing will ever work becomes a self-fulfilling prophecy that makes you less likely to engage fully with new treatments.
Spravato represents hope grounded in solid evidence. It is not wishful thinking or unproven alternative medicine, but an FDA-approved treatment backed by years of research. For many people, knowing that a fundamentally different mechanism exists, one that often works when traditional approaches haven’t, changes something fundamental.
We see this at our Fort Worth clinic regularly. Patients come in exhausted, skeptical, but willing to try one more thing. Then something shifts, not always immediately, not always completely, but enough to remember that change is possible. That shift often precedes measurable improvements in depression symptoms.
Taking the Next Step
If you’re reading this because you or someone you love has been struggling with treatment-resistant depression, you know how isolating and exhausting it is. You know how many well-meaning people have suggested things you’ve already tried, how many times you’ve hoped a new medication would finally be the one that works, how much courage it takes to keep trying when you’ve been disappointed before.
Spravato for treatment-resistant depression isn’t a miracle cure. But for many people, it’s the treatment that finally breaks through when others haven’t. Clinical research and real-world outcomes both support its effectiveness. More importantly, we’ve seen how it can create genuine turning points in people’s lives.
At Nura Therapy, we understand treatment-resistant depression because we specialize in treating it. Our Fort Worth clinic offers Spravato treatment in a supportive, medically supervised environment. We take insurance, work with you on scheduling, and provide the kind of care that recognizes you’re not just a diagnosis, you’re a person who deserves to feel better.
You can learn more about our approach to anxiety treatment, PTSD treatment, and other conditions that often co-occur with depression. We also offer comprehensive information about OCD treatment and chronic pain treatment, conditions where ketamine-based therapies are showing promising results.
Treatment-resistant depression has stolen enough from you. If traditional approaches haven’t worked, it’s worth exploring whether Spravato might offer a different path forward. Call us at Nura Therapy or reach out through our website to schedule a consultation. Let’s talk about whether this treatment might help you write a different story about your depression, one where you’re not stuck anymore.
Nura Therapy
4622 Saint Amand Circle
Fort Worth, TX 76126
The information on this page is for educational purposes only and does not constitute medical advice. Individual results may vary. Always consult with a qualified healthcare provider before beginning any new treatment. Spravato (esketamine) is an FDA-approved prescription medication that must be administered under medical supervision in certified healthcare settings.